Home
  >  
Section 40
  >  
Chapter 39,605

Combination effect of caffeine and cisplatin on a cisplatin resistant human lung cancer cell line

Ohsaki, Y.; Ishida, S.; Fujikane, T.; Akiba, Y.; Osanai, S.; Onodera, S.

Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(7): 1339-1343

1990

ISSN/ISBN: 0385-0684
PMID: 2369137
Accession: 039604469
The development of resistance to anti-cancer drugs is a major factor in limiting the response rate of cancer chemotherapy. Several mechanisms of such resistance are reported. Recently, expression of MDR gene and synthesis of p-glycoprotein by the MDR gene was reported as a mode of multi-drug resistance, but the mechanism of the resistance to cisplatinum (CDDP) remains unclear. Detoxification of CDDP, increase of the efflux of the drug and increase of DNA repair are considered to be the mode of CDDP resistance. It is widely documented that caffeine enhances the cytocidal effect of certain anti-cancer agents. The inhibition of DNA repair by caffeine has been considered to be one mechanism which enhances the cytocidal effect of such agents. We conducted the present study to evaluate the combination effect of caffeine and CDDP on the human lung adenocarcinoma cell line PC9/P and its CDDP resistant cell line PC9/R. Cell growth inhibition was measured by clonogenic assay and cell cycle analysis was performed with propidium iodide (PI) stain using flow cytometer (FCM). Caffeine enhanced the effect of CDDP on PC9/P synergistically. However, the combination effect of the two drugs was not apparent on PC9/R. Caffeine decreased G2M accumulation due to CDDP exposure in both cell lines. The data indicate that caffeine does not overcome the resistance of PC9/R, whereas caffeine enters PC9/R. It is suggested that increase of DNA repair might not be a mode of the CDDP resistance of PC9/R.

PDF emailed within 1 workday: $29.90




Related References

Campling, B.G.; Jain, N.; Cole, S.P.C.; Deeley, R.G.; Gerlach, J.H. 1997: Energy dependent reduction of cisplatin accumulation in a cisplatin-resistant human small cell lung cancer (Sclc) cell line Lung Cancer 18: 143-144
Meijera, C.; van Luyn, M.J.; Nienhuis, E.F.; Blom, N.; Mulder, N.H.; de Vries, E.G. 2001: Ultrastructural morphology and localisation of cisplatin-induced platinum-DNA adducts in a cisplatin-sensitive and -resistant human small cell lung cancer cell line using electron microscopy Biochemical Pharmacology 61(5): 573-578
Bungo, M.; Nakagawa, K.; Saijo, N. 1990: A mechanism of cisplatin resistance in a cisplatin resistant lung cancer cell line Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(3 Part 2): 515-516
Sawada, S.; Mese, H.; Sasaki, A.; Yoshioka, N.; Matsumura, T. 2003: Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line Cancer ChemoTherapy and Pharmacology 51(6): 505-511
Chen, Y.; Li, J.; Chen, S.; Zhang, Y.; Hu, Y.; Zhang, G.; Yan, X.; Jiao, S. 2017: Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer Scientific Reports 7(1): 10760
Wang, W.; Chen, P.; Li, J.-l.; Pei, Y.-f.; Shuang, Q.-c.; Liu, C.-H.; Cai, S.; Liu, S.-k.; Zhu, L.-y.; Zhou, R. 2009: Tumstatin185-191 increases the sensitivity to cisplatin in a cisplatin-resistant human lung adenocarcinoma cell line Zhonghua Zhong Liu Za Zhi 31(8): 577-581
Chau, Q.; Stewart, D.J. 1999: Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant Cancer ChemoTherapy and Pharmacology 44(3): 193-202
Hettinga, J.V.; Lemstra, W.; Meijer, C.; Mulder, N.H.; Konings, A.W.; de Vries, E.G.; Kampinga, H.H. 1994: Hyperthermic potentiation of cisplatin toxicity in a human small cell lung carcinoma cell line and a cisplatin resistant subline International Journal of Hyperthermia: the Official Journal of European Society for Hyperthermic Oncology North American Hyperthermia Group 10(6): 795-805
Chen, G.; Zeller, W. 1992: Synergistic potentiation of Cisplatin cytotoxicity by caffeine in a Cisplatin-resistant rat ovarian tumor-cell line International Journal of Oncology 1(2): 129-134
Blackhall, F.H.; O'brien, M.; Schmid, P.; Nicolson, M.; Taylor, P.; Milenkova, T.; Kennedy, S.J.; Thatcher, N. 2010: A phase i study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 5(8): 1285-1288
Zhan, M.; Liu, X. 1999: Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP Chinese Medical Journal 112(4): 336-339
Ma, J.; Maliepaard, M.; Kolker, H.J.; Verweij, J.; Schellens, J.H. 1998: Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1 Cancer ChemoTherapy and Pharmacology 41(3): 186-192
Morikage, T.; Ohmori, T.; Nishio, K.; Fujiwara, Y.; Takeda, Y.; Saijo, N. 1993: Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines Cancer Research 53(14): 3302-3307
Bungo, M.; Kaneko, M.; Nakagawa, K.; Minato, K.; Horichi, N.; Niimi, S.; Fujiwara, Y.; Sasaki, Y.; Saijo, N. 1989: Formation and repair of dna interstrand crosslinking by cisplatin in human lung cancer cell lines sensitive and resistant to cisplatin Proceedings of the American Association for Cancer Research Annual Meeting 30: 490
Nishio, M.; Arioka, H.; Nishio, K.; Kubota, N.; Heike, Y.; Ohata, M.; Saijo, N. 1994: Overexpression of cisplatin-inducible proteins that are recognized by anti-HMG antibody in cisplatin-resistant human lung cancer cell lines Cellular Pharmacology 1(6): 251-255
Li, P.; Wang, K.; Zhang, J.; Zhao, L.; Liang, H.; Shao, C.; Sutherland, L.C. 2012: The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin Cancer Epidemiology 36(5): 481-489
Mary, O.; Krzystof, K.; Baktiar, H.; Meerbeeck Jan, V.; Paul, B.; Paul, L.; Lionel, B.; Ernest, M.; Frederique, B.; Sabine, M.; Christian, F.; Jos, A.S.; D, A.M.C. 2011: Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer ― EORTC 08062 European Journal of Cancer (1990) 47(15): 2322-2330
O'Brien, M.E.R.; Konopa, K.; Lorigan, P.; Bosquee, L.; Marshall, E.; Bustin, F.; Margerit, S.; Fink, C.; Stigt, J.A.; Dingemans, A.M.C.; Hasan, B.; Van Meerbeeck, J.; Baas, P. 2011: Randomised phase Ii study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062 European Journal of Cancer 47(15): 2322-2330
Masuda, H.; Tanaka, T.; Matsushima, S.; Kusaba, I. 1992: Selective potentiation of cisplatin in combination with amphotericin B and aphidicolin against a resistant human ovarian cancer cell line The Cancer Journal 5(2): 96-100
Fujiwara, Y.; Sugimoto, Y.; Kasahara, K.; Bungo, M.; Yamakido, M.; Tew, K.D.; Saijo, N. 1990: Determinants of drug response in a cisplatin-resistant human lung cancer cell line Japanese Journal of Cancer Research: Gann 81(5): 527-535